Chlamydia pneumoniae uses peripheral blood monocytes (PBMC) for systemic dissemination and has been linked to atherogenesis by inflammation mediated via TLR2/4 and CD14. We found 12.8% of 610 coronary artery disease (CAD) patients of Central European background to be chronically infected with C. pneumoniae based on the repeated detection of chlamydial DNA in PBMC. Among those the À159C4T CD14 promoter polymorphism was more frequent (OR 1.7, 95% CI 1.08-2.65, P ¼ 0.0224) than among C. pneumoniae-negative subjects matched for age and gender. The Arg753Gln TLR2 and Asp299Gly TLR4 polymorphisms were not related to chlamydial infection. Susceptibility for chronic chlamydial infection of PBMC in CAD patients appears associated with the CD14-159C4T promoter polymorphism encoding for enhanced CD14 expression.
Recurrent bacterial and viral infections have been related to the development of atherosclerosis through interference with the vascular inflammatory and coagulant equilibrium. 1 Activation of Toll-like receptor (TLR) 2, TLR4 and CD14 is considered to be crucial in this process. The obligate intracellular bacterium Chlamydia (Chlamydophila) pneumoniae is frequently found in atherosclerotic lesions and appears to use blood monocytes (PBMC) as a vector for its dissemination within the circulation. 2 Chlamydial interaction with pattern recognition receptors of the innate immune system results in uptake of the pathogen and MAPkinase-dependent inflammatory signalling. 3 Chlamydial heat-shock protein 60 (cHSP60) mediates inflammation in endothelial cells and macrophages via the TLR4-MD2 complex and the MyD88-dependent pathway. 4 TLR2 activation by C. pneumoniae induces proinflammatory cytokines (TNF-a, IL-1b) in blood monocytes. 5 Chlamydial lipopolysaccharide (LPS) stimulates monocytes to express cytokines, chemokines, growth factors, and procoagulant factors via the LPS-binding receptor CD14, which recognizes bacterial LPS as well as heat-shock protein 60. 6 Vascular cells lacking membrane-bound CD14 protein are stimulated by soluble CD14 complexed to LPS. The À159C4T CD14 promoter polymorphism is associated with myocardial infarction in older patients with a low atherosclerotic risk profile. 7 This common single nucleotide polymorphism (SNP) in the proximal CD14 promoter region encodes for increased transcriptional activity in mononuclear cells resulting in significantly enhanced CD14 expression and increased release of soluble CD14 in homozygous carriers of the T allele. 8 It may thus predispose to an increased inflammatory response to infectious stimuli. Previously, enhanced frequencies of the Arg753Gln TLR2 and Asp299Gly TLR4 polymorphisms were found in patients with staphylococcal sepsis or Gram-negative infections in critically ill patients. 9, 10 We thus examined whether the chronic C. pneumoniae infection in coronary artery disease (CAD) patients is related to the prevalence of these genetic variations in TLR2, TLR4 or CD14. We focused on 78 CAD patients determined to be chronically infected with C. pneumoniae as defined by consistent detection of C. pneumoniae DNA in their PBMC fraction up to 1 year.
In total, 610 Caucasian patients admitted to the emergency room because of acute chest pain were diagnosed as having unstable angina pectoris or myocardial infarction on the basis of coronary angiography, electrocardiography, clinical presentation, and laboratory parameters. All patients had a central European background, subjects from other ethnicities, for example, Turkish, were excluded. In addition, analysis of the Hardy-Weinberg's equilibrium revealed no differences in allele distributions. For analysis of C. pneumoniae carriage in blood monocytes and determination of the polymorphisms (À159C4T CD14 promoter, Arg753Gln TLR2, Asp299Gly TLR4) 10 ml blood was collected on admission (preceding coronary angiography and medical treatment) and within 1 year thereafter. Chlamydial infection of PBMC at the time of admission was present in 157 of 610 CAD patients (25.8%) initially enrolled ( Table 1 ). Repeated C. pneumoniae DNA detection in the PBMC fraction of two independent blood samples within 1 year after admission was defined as chronic infection of PBMC and was detected in 12.8% (n ¼ 78) of CAD patients. All subjects in the study population had coronary artery disease, and it was not our aim to describe infection as a risk for developing atherosclerosis but to analyze the susceptibility to chronic chlamydial infection in relation to the genetic background. For comparison of the distribution of TLR2, TLR4 and CD14 promoter SNPs these continuously C. pneumoniae DNApositive CAD patients were therefore matched by sex and age to 78 constantly C. pneumoniae DNA-negative subjects from the study population. No significant differences in the severity of coronary artery disease were observed by coronary angiography between these matched groups. Anti-chlamydial IgG antibodies were more frequently found in C. pneumoniae DNA-positive patients (95%) compared to C. pneumoniae DNA-negative patients (67%), whereas serological titers of IgG, IgA and IgM against C. pneumoniae did not differ between the matched groups ( Table 1) .
The genotype distribution in CAD patients with and without chronic C. pneumoniae infection of blood monocytes is indicated in Table 2 . Chronically C. pneumoniaeinfected CAD patients were significantly more likely to carry the T allele in the CD14 promoter at position À159 (OR ¼ 1.7, 95% CI 1.08-2.65; P ¼ 0.0224) than C. pneumoniae-negative patients. Interestingly, there was no significant difference in the T allele frequencies between C. pneumoniae-negative and C. pneumoniae-positive patients at the time of admission (data not shown), thus only the susceptibility to chronic chlamydial infection seems associated with the polymorphism.
Regarding the Arg753Gln TLR2 and Asp299Gly TLR4 receptor polymorphisms no significant differences in the distribution of the mutant allele frequencies between chronically infected and noninfected patients were observed by melting-curve analysis of fluorescence labeled oligonucleotide hybridization probes on the LightCyclert instrument (Roche Diagnostics, Mannheim/ Germany; in analogy to reference 11 ). The Arg753Gln TLR2 polymorphism was found in 3.9% of CAD patients without correlation to C. pneumoniae infection (P ¼ 1.0), Table 1 Patient characteristics and C. pneumoniae (Cp) antibody titers (median) in the total study population (n ¼ 610) and in the patient group with chronic Cp infection in PBMC matched by age and gender to Cp-negative patients
Study population
Matched groups
Cp DNA negative Matched group of constantly C. pneumoniae DNA-negative patients. PBMC from the 610 study patients were separated in a Ficoll-Histopaque density gradient (Sigma, St Louis, MO, USA). 2 For C. pneumoniae detection, purified DNA was resuspended in 100 ml water and subjected to PCR using the HL-1/HR-1 primers that amplify a genomic 438-bp C. pneumoniae target sequence. For enhanced specificity, a nested PCR protocol was used with the nested oligonucleotide primer pair In-1 (5 0 -AGT TGA GCA TAT TCG TGA GG-3 0 ) and In-2 (5 0 -TTT ATT TCC GTG TCG TCC AG-3 0 ), which yield a 128-bp product. For confirmation, nonradioactive DNA hybridization was performed using oligonucleotide HM-1 3 0 -tailed with digoxigenin-11-dUTP/dATP (Roche Diagnostics) as the probe.
2 Sera were tested for C. pneumoniae-specific antibodies with a microimmunofluorescence (MIF) assay (IgG, IgA, IgM; Labsystems, Helsinki/Finland). MIF-anti-C. pneumoniae IgG titer X1 : 16 indicated previous C. pneumoniae infection. 7 Primer pairs for detection of the CD14-159T mutation were 5 0 -GTG CCA ACA GAT GAG GTT CAC-3 0 and 5 0 -GCC TCT GAC AGT TTA TGT AAT C-3 0 . PCR products were digested with AvaII and visualized by polyacrylamide-gel electrophoresis. Statistics were calculated by using the STATISTICA software (StatSoft Inc., OK/US) for Windows. Variables of the allele distributions for the matched groups were checked by w 2 analysis (significance Po0.05).
whereas the Asp299Gly TLR4 polymorphism was found in 6.1% of C. pneumoniae DNA-negative CAD patients and 4.0% of CAD patients persistently infected with C. pneumoniae (P ¼ 0.452, data not shown).
Genetic variations encoding for functional changes in the cellular receptor pattern of the innate immune system have been incriminated to affect the emergence and severity of bacterial infections. Furthermore, the progress of chronic inflammatory diseases like atherosclerosis has been associated with a genetic background that putatively predisposes patients to an enhanced inflammatory immune response. We were interested whether the susceptibility to chronic C. pneumoniae infection in blood monocytes of CAD patients, which has been linked to the development of atherosclerotic disease, 2 is associated with the distribution of SNPs in TLR2, TLR4 and the CD14 molecule. Unkelbach et al 7 could show that the CD14 À159C4T promoter polymorphism is associated with myocardial infarction, especially in patients older than 62 years with a low atherosclerotic risk profile regarding the classical risk factors. The functional relevance of the C-to-T exchange at position À159 of the CD14 promoter region lies in the higher plasma levels of soluble CD14, and enhanced membrane expression of CD14 on monocytes in patients carrying the T allele. 8 In our study, chronic C. pneumoniae infection but not once-only C. pneumoniae DNA detection in blood monocytes from CAD patients was significantly enhanced in patients carrying the T allele. Importantly, the distribution of the allele frequencies in the matched group of noninfected patients was in accordance with previous reports from CAD patients in the same age group. 7 Therefore, we hypothesize that mutations in the CD14 promoter leading to enhanced CD14 expression may facilitate chlamydial uptake in blood monocytes and subsequent vascular inflammation. Forthcoming studies will show whether the expression of soluble and membranebound CD14 is correlated with chlamydial persistence in CAD patients carrying the T allele, resulting in enhanced cellular signalling cascades of inflammation mediated via the CD14/TLR4-MD2 complex. This may alter leukocyte-endothelial cell 'cross-talk' and leukocyte recruitment to vascular tissues as initial step in atherogenesis, both modified by close interactions between CD14 and TLR4. 12 Interestingly, Eng et al 13 recently found previous C. pneumoniae infection in healthy subjects to be correlated with this CD14 SNP, which also has been reported to regulate CD14 density on mononuclear cells. In our study, serological testing of C. pneumoniae antibody titers was an inadequate marker for the prediction of persistent C. pneumoniae infection in CAD patients, which is in concordance with disappointing results from large seroepidemiological surveys and in support of the recent recommendation from the CDC not to use serology for diagnosis of chronic infection. 14 Indeed, there is a general lack of a common standard to diagnose chronic vascular C. pneumoniae infection. Therefore, we made for the first time the attempt to define chronic vascular C. pneumoniae infection by repeated detection of chlamydial DNA in blood monocytes within 1 year. The base for that approach was a PCR protocol previously widely applied for vascular samples, 2 that takes into account recent validation criteria recommended by the CDC/USA and the Laboratory Centre for Disease Control/Canada. 14 The observed mutant allele frequencies of the Arg753Gln TLR2 and Asp299Gly TLR4 polymorphisms in our study population did not differ with respect to chronic C. pneumoniae infection in PBMC. The Arg753Gln TLR2 polymorphism was previously found in 2.8-9.4% of healthy subjects, 15 whereas detection of Asp299Gly TLR4 was indicated with 5.9% in healthy blood donors. 16 Initially seen as related to severe bacterial Gram-positive and Gram-negative infections, 9,10 in vitro studies recently described a limited functional relevance of the Asp299Gly mutation in the TLR4 receptor for the innate immune response, as monocytes from individuals with heterozygous allele distribution exhibited no deficit in the recognition of bacterial LPS. 17 In conclusion, this study indicates that chronic C. pneumoniae infection of blood monocytes is detectable in 12.8% of CAD patients and associated with the presence of the T allele in the CD14 promoter region at position À159. Our study focuses on a genetic marker in a large group of chronically infected CAD patients, but does not allow to link chronic C. pneumoniae infection to atherosclerotic disease development or disease severity. More extensive studies are needed to evaluate the relevance of C. pneumoniae infection in patients with different genotypes with respect to corresponding risk factors, inflammatory immune response and stage of the atherosclerotic disease. This may result in a better specification of patients persistently infected with C. pneumoniae based on a genetic background, and may help to investigate the pathogenetic role of C. pneumoniae in atherosclerotic disease.
